To the Editor,

Accumulating evidence suggests that a subgroup of patients with severe COVID-19 might have a cytokine storm syndrome associated with acute respiratory distress syndrome (ARDS), multiple organ failure and increased mortality. This syndrome is characterised by increased interleukin (IL)-2, IL-7, granulocyte colony stimulating factor, interferon-γ inducible protein 10, monocyte chemoattractant protein 1, macrophage inflammatory protein 1-α, and tumour necrosis factor (TNF)-α [@b0005].

N-Acetylcysteine (NAC), a well-known mucolytic agent used in respiratory infections, is a thiol-containing free-radical scavenger and a precursor of glutathione [@b0010]. Reactive oxygen species and oxidative stress activate important redox-sensitive transcription factors like NF-κB and activator protein-1, which lead to the co-ordinate expression of proinflammatory genes of IL-6, IL-8, and TNF-α [@b0015].

The beneficial action of 1200 mg/d of oral NAC in respiratory diseases has been previously demonstrated in prevention of chronic obstructive pulmonary disease exacerbations [@b0010]. Moreover, a recent study including patients with community-acquired pneumonia, showed that the addition of this dose of NAC to conventional treatment improves oxidative stress and inflammatory response [@b0020]. The positive effects of NAC in viral lower respiratory tract infections have been associated with inhibition of IL-8, IL-6, and TNF-α expression and release in alveolar type II cells infected with influenza virus A and B and respiratory syncytial virus [@b0025].

The results of these studies offer reasonable basis for the addition of 1200 mg/d oral NAC on therapeutic schemes of patients with COVID-19, as a measure that could potentially prevent the development of the cytokine storm syndrome and ARDS. This hypothesis is worth clarifying in appropriately designed clinical studies.

Prior presentation {#s0005}
==================

No data from this manuscript were presented in a scientific meeting before.

Funding sources {#s0010}
===============

The article has no funding source.

Declaration of Competing Interest
=================================

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
